Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
nL-GARS1-001 in Charcot-Marie-Tooth Type 2D
NCT07226297Phase 2Enrolling by invitation
- Sponsor
- n-Lorem Foundation
- Start
- Oct 2025
- Primary completion
- Oct 2027
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nL-GARS1-001 in Charcot-Marie-Tooth disease type 2D (CMT2D), sponsored by n-Lorem Foundation. Primary endpoint: Motor Skills at 24 months. Started Oct 2025; status: enrolling by invitation.
02
Drugs
nL-GARS1-001
03
Conditions
Charcot-Marie-Tooth disease type 2D (CMT2D)
Beyond the preview
Go deeper on NCT07226297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07226297.